Patent ID: 9533039
Date: 2017-01-03
CPC Classifications: A61K,C07K

Claim:
1. A method of treating systemic lupus erythematosus (SLE) comprising administering to a subject in need thereof a therapeutically effective amount of an antibody of antigen-binding fragment thereof that specifically binds CD48 (SEQ ID NO:384) and blocks the interaction between human CD48 and a CD48 receptor, wherein the CD48 receptor is either human CD2 (SEQ ID NO: 392) or human 2B4 (SEQ ID NO: 390), and wherein the antibody or antigen-binding fragment thereof comprises the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 368 and the CDRs of a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 370.